Di Costanzo E, Rovea A
Servizio Psichiatrico, USSL 12 Sinistra Piave, Conegliano, Treviso.
Minerva Psichiatr. 1992 Oct-Dec;33(4):301-4.
A double-blind study was performed to evaluate carbamazepine for the prophylaxis of benzodiazepine withdrawal syndrome in elderly patients--a controversial subject despite the extensive use of such drugs in old age. Thirty-six outpatients aged > or = 60 yrs suffering from general anxiety disorders and benzodiazepine abuse underwent gradual discontinuation of benzodiazepine therapy in two groups, one treated with carbamazepine and one with placebo. The carbamazepine-treated group demonstrated a lower incidence of withdrawal symptoms rated according to the Physician Withdrawal Check List (p < 0.01), better results with the Hopkins Symptom Check List (Covi cluster, p < 0.01) and a more markedly reduced score with the Hamilton Rating Scale for Anxiety (p < 0.05). Only 3 out of 18 patients in said group complained of side effects attributable to carbamazepine, which disappeared at lower dosages.
进行了一项双盲研究，以评估卡马西平对老年患者苯二氮䓬类药物戒断综合征的预防作用——尽管此类药物在老年人群中广泛使用，但这仍是一个有争议的话题。36名年龄≥60岁、患有广泛性焦虑症且滥用苯二氮䓬类药物的门诊患者被分为两组，一组接受卡马西平治疗，另一组接受安慰剂治疗，两组均逐渐停用苯二氮䓬类药物治疗。根据医生戒断检查表评估，接受卡马西平治疗的组戒断症状发生率较低（p<0.01）；根据霍普金斯症状检查表（科维组，p<0.01）评估，该组效果更好；根据汉密尔顿焦虑量表评估，该组得分降低更为明显（p<0.05）。该组18名患者中只有3名抱怨有卡马西平所致的副作用，且在较低剂量时副作用消失。
